Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
History
Sirtris Pharmaceuticals was founded in 2004, by venture capitalist and biotech entrepreneur Christoph Westphal, MD, PhD. The company was acquired by pharmaceutical giant GlaxoSmithKline in 2008, in a deal worth $720 million.
Mission
At Sirtris, our mission is to discover, develop and commercialize innovative, targeted therapies to treat and cure metabolic and inflammatory diseases and improve the lives of patients.
Vision
Our vision is to be the world leader in developing small molecule drugs to treat metabolic and inflammatory diseases and to change the practice of medicine.
